Cetera Investment Advisers decreased its position in Zoetis Inc (NYSE:ZTS) by 6.8% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 5,727 shares of the company’s stock after selling 420 shares during the period. Cetera Investment Advisers’ holdings in Zoetis were worth $712,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Commerce Bank lifted its stake in Zoetis by 1.5% in the 2nd quarter. Commerce Bank now owns 81,495 shares of the company’s stock valued at $9,249,000 after acquiring an additional 1,198 shares in the last quarter. Barrett Asset Management LLC increased its position in shares of Zoetis by 385.6% during the 2nd quarter. Barrett Asset Management LLC now owns 189,195 shares of the company’s stock worth $21,472,000 after purchasing an additional 150,235 shares during the last quarter. Echo Street Capital Management LLC increased its position in shares of Zoetis by 46.1% during the 2nd quarter. Echo Street Capital Management LLC now owns 289,327 shares of the company’s stock worth $32,836,000 after purchasing an additional 91,304 shares during the last quarter. Callahan Advisors LLC increased its position in shares of Zoetis by 80.0% during the 3rd quarter. Callahan Advisors LLC now owns 11,610 shares of the company’s stock worth $1,447,000 after purchasing an additional 5,160 shares during the last quarter. Finally, James Investment Research Inc. acquired a new position in shares of Zoetis during the 3rd quarter worth approximately $790,000. Hedge funds and other institutional investors own 89.97% of the company’s stock.
ZTS stock opened at $117.92 on Friday. The company has a current ratio of 4.39, a quick ratio of 3.02 and a debt-to-equity ratio of 2.47. The firm has a market capitalization of $56.09 billion, a PE ratio of 37.67, a PEG ratio of 2.87 and a beta of 0.88. Zoetis Inc has a 1-year low of $78.90 and a 1-year high of $130.20. The business’s 50 day simple moving average is $124.49 and its 200 day simple moving average is $116.95.
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Tuesday, October 22nd will be issued a dividend of $0.164 per share. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.56%. The ex-dividend date of this dividend is Monday, October 21st. Zoetis’s payout ratio is presently 21.09%.
In related news, EVP Kristin C. Peck sold 11,500 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $117.16, for a total transaction of $1,347,340.00. Following the transaction, the executive vice president now directly owns 44,877 shares of the company’s stock, valued at approximately $5,257,789.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Clinton A. Jr. Lewis sold 6,123 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $128.62, for a total value of $787,540.26. Following the transaction, the executive vice president now directly owns 39,141 shares in the company, valued at $5,034,315.42. The disclosure for this sale can be found here. Insiders have sold a total of 34,332 shares of company stock worth $4,143,304 over the last three months. 0.29% of the stock is owned by insiders.
Several research analysts have weighed in on the company. ValuEngine lowered Zoetis from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Barclays boosted their price target on Zoetis from $120.00 to $135.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Morgan Stanley boosted their price target on Zoetis from $100.00 to $136.00 and gave the stock an “equal weight” rating in a research report on Monday, September 30th. Stifel Nicolaus set a $140.00 price target on Zoetis and gave the stock a “buy” rating in a research report on Friday, September 13th. Finally, JPMorgan Chase & Co. boosted their price target on Zoetis from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Friday, November 8th. Eight research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Zoetis currently has a consensus rating of “Buy” and an average target price of $126.75.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.